Uterine sarcomas

Arrastia CD, Fruchter RG, Clark M, et al. (1997) Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65: 158–163

Berchuck A, Rubin SC, Hoskins WJ, et al. (1988) Treatment of uterine leiomyosarcoma, Obstet. Gynecol 71: 845–850

Bitterman P, Chun B, Kurman RJ (1990) The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 14: 317–328

Curtin JP, Blessing JA, Soper JT, et al. (2001) Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 83: 268–270

Delaloge S, Pautier P, Duvillard P (2004) Tamoxifen-related uterine malignancies: carcinomas or sarcomas? Int J Gynecol Cancer 14: 395

Ferrer F, Sabater S, Farrus B, et al. (1999) Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 44: 47–52

George M, Pejovic MH, Kramar A (1986) Uterine sarcomas: prognostic factors and treatment modalities. Study on 209 patients. Gynecol Oncol 24: 58–67

Harlow BL, Weiss NS, Lofton S (1986) The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76: 399–402

Hensley ML, Maki R, Venkatraman E, et al. (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 15(20): 2824–2831

Jones GW, Chouinard E, Patel M (1991) Adjuvant adriamycin (Doxorubicin®) in adult patient with soft tissue sarcoma: a systematic overview and quantitative meta-analysis. Clin Invest Med 14 (Suppl 19): A772

Kloos I, Delaloge S, Pautier P, et al. (2002) Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 12(5): 496–500

Knocke TH, Kucera H, Dorfler D, et al. (1998) Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 83: 1972–1979

Kohorn EI, Schwartz PE, Chambers JT, et al. (1986) Adjuvant therapy in mixed müllerian tumors of the uterus. Gynecol Oncol 23: 212

Kuo YS, Timmins P, Blank SV, et al. (2006) Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium. Gynecol Oncol 100: 160–165

Lanxman R, Currie JL, Kurman RJ, et al. (1993) Cytogenetic profile of uterine sarcomas. Cancer 71: 1283–1288

Leitao MM, Brennan MF, Hensley M, et al. (2004) Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma. Gynecol Oncol 87: 287–294

Le Péchoux C, Pautier P, Delannes M, et al. (2006) Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma). Cancer Radiother 10(4): 185–207

Levenback CF, Tortolero-Luna G, Pandey DK, et al. (1996) Uterine sarcoma. Obstet Gynecol Clin North Am 23: 457–473

Liu FS, Kohler MF, Marks JR, et al. (1994) Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83: 118–124

Major FJ, Blessing JA, Silverberg SG, et al. (1993) Prognostic factors in early-stage uterine sarcoma. A gynecologic Oncology Group Study. Cancer 71(Suppl 1): 1702–1709

Malmström H, Schmidt H, Persson PG, et al. (1992) Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators. Gynecol Oncol 44: 172–177

Marchese MJ, Liskow AS, Crum CP, et al. (1984) Uterine sarcomas: a clinicopathologic study, 1965–1981. Gynecol Oncol 18: 299–312

Meredith RF, Eisert DR, Kaka Z, et al. (1986) An excess of uterine sarcomas after pelvic irradiation. Cancer 58: 2003–2007

Muss HB, Bundy B, DiSaia PJ, et al. (1985) Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicine versus doxorubicine and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 55: 1648–1653

Norris HJ, Taylor (1966) Mesenchymal tumors of the uterus A clinical and pathological study of 53 endometrial stromal tumors. Cancer 19: 755–766

Omura GA, Blessing JA, Major F, et al. (1985) Randomized clinical trial of adjuvant Adriamycine in uterine sarcomas: a Gynecologic Oncologic Group study. J Clin Oncol 3: 1240–1245

Omura GA, Major F, Blessing JA, et al. (1983) Randomized study of adriamycin with and without dimethyl triazinoimidazole carmoxamide in advanced uterine sarcomas. Cancer 52: 626–632

Pautier P, Genestie C, Rey A, et al. (2000) Analysis of clinicopathological prognostic factors in 157 uterine sarcoma: interest of a grading score validated in soft tissue sarcoma. Cancer 88: 1425–1431

Pautier P, Genestie C, Fizazi K, et al. (2002) Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer 12: 749–754

Pautier P, Rey A, Haie-Meder C, et al. (2004) Adjuvant chemotherapy with cisplatin, ifosfamide and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 14(6): 1112–1117

Podczaski ES, Woomert CA, Stevens CW (1989) Management of malignant mixed mesodermal tumors of the uterus. Gynecol Oncol 32: 240–244

Salazar OM, Bonfiglio TA, Patten SF, et al. (1978) Uterine sarcomas: natural history, treatment, and prognosis. Cancer 42: 1152–1160

Silverberg SG, Major FJ, Blessing JA, et al. (1990) Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology group pathology study of 203 cases. Int J Gynecol Pathol 23: 1–19

Slayton RE, Blessing JA, Angel C, et al. (1987) Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 71: 1303–1304

Slayton RE, Blessing JA, Clarke-Pearson D (1991) A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study. Invest New Drugs 9: 93–94

Slayton RE, Blessing JA, DiSaia PJ, et al. (1987) Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 71: 661–662

Slayton RE, Blessing JA, Look K, et al. (1991) A phase II trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study. Invest New Drugs 9: 207–208

Sorbe B (1985) Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 20: 281–289

Sutton G, Blessing J, Barrett R, et al. (1992) Phase II trial of ifosfamide and mesna in leimyosarcoma of the uterus: a Gynecologic Oncologic Group study. Am J Obstet Gynecol 166: 556–559

Sutton GP, Blessing JA, Rosenheim N, et al. (1989) Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus. Am J Obstet Gynecol 161: 309–312

Sutton GP, Stehman FB, Michael H, et al. (1986) Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 685: 709–714

Sutton PG, Blessing JA, Ball HG (1997) A phase II of paclitaxel in patients with advanced or recurrent uterine leiomyosarcomas unexposed to other chemotherapy: a Gynecologic Oncology Group study. Proceedings of the American Society of Clinical Oncology (ASCO), Abstract 1302

Sutton G, Blessing JA, Malfetano JH (1996) Ifosfamide and doxorubicine in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 62: 226–229

Thigpen JT, Blessing, Beecham J, et al. (1991) Phase II trial of cisplatine as first line chemotherapy in patients with advanced or recurrent uterine sarcomas (a Gynecologic Oncology Group study). J Clin Oncol 9: 1962–1966

Thigpen JT, Blessing, Orr JW Jr, et al. (1986) Phase II trial of cisplatine in treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. Cancer Treat Rep 70: 271–274

Van Geel AN, Pastorino U, Jauch KW, et al. (1996) Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 15: 675–682

Verweij J, Seynaeve C (1999) The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Sem Rad Oncol 9: 352–359

Wheelock JB, Krebs HB, Schneider V, et al. (1985) Uterine sarcoma: analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 151: 1016–1022

Wolfson AH, Wolfson DJ, Sittler SY, et al. (1994) A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 52: 56–62

Wysowski DK, Honig SF, Beitz J (2002) Uterine sarcoma associated with tamoxifen use. N Engl J Med 346: 1832–1833

Young JL, Percy CL, Asire AJ, et al. (1981) Cancer incidence and mortality in the United States, 1973–77. Natl Cancer Inst Monogr 57: 1–187